Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study
This study demonstrated that a T2D intervention combining technology-enabled continuous remote care with individualized care plans encouraging nutritional ketosis can significantly reduce HbA1c, medication use, and weight within 70 days , and that these outcomes can be maintained or improved through 1 year. Most intervention participants with HbA1c reported at 1 year achieved glycemic control in the sub-diabetes range with either no medication or the use of metformin alone. Related health parameters improved including blood pressure, lipid-lipoprotein profile, inflammation, and liver function.
Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis resulting in hyperglycemia. Although current diabetes treatments have exhibited some success in lowering blood glucose, their effect is not always sustained and their use may be associated with undesirable side effects, such as hypoglycemia. Novel diabetic drugs, which may be used in combination with existing therapies, are therefore needed. The potential of specifically targeting the liver in order to normalize blood glucose levels has not been fully exploited. Here, we review the molecular mechanisms controlling hepatic gluconeogenesis and glycogen storage, and assess the prospect of therapeutically targeting associated pathways to treat type 2 diabetes.
As important as it is to get your diet right to prevent diabetes, you should also consider the possible role of medications you may be on. Statin induced diabetes and its clinical implications.